



April 30, 2019

## Veracyte Announces First Quarter 2019 Financial Results

*Grew Revenue by 47% to \$29.5 Million*

*Grew Genomic Test Volume by 33% to 9,162 Tests*

*Company Raises 2019 Annual Revenue Guidance*

*Conference Call and Webcast Today at 5:00 p.m. ET*

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 30, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.

"We delivered excellent results in the first quarter of 2019," said Bonnie Anderson, chairman and chief executive officer of Veracyte. "Product revenue and genomic volume both grew significantly in the quarter, and our biopharmaceutical service revenue exceeded our expectations. We also demonstrated financial discipline, improving our cash used in operating activities by 86%."

Anderson continued, "In addition, we received a final Medicare coverage decision for our Envisia Genomic Classifier and published clinical validation and clinical utility data in *The Lancet Respiratory Medicine*, positioning the test for commercial expansion nationwide. With this continued strong momentum, we believe we remain well-positioned for both near- and long-term growth."

### First Quarter 2019 Financial Results

*For the first quarter of 2019, as compared with the first quarter of 2018:*

- Revenue was \$29.5 million, an increase of 47%; excluding biopharmaceutical services revenue, revenue was \$25.4 million, an increase of 27%;
- Gross Margin was 71%, an improvement of 1,000 basis points or 10 percentage points;
- Operating Expenses, Excluding Cost of Revenue, were \$23.1 million, an increase of 9%;
- Net Loss and Comprehensive Loss was \$1.9 million, an improvement of 79%;
- Basic and Diluted Net Loss Per Common Share was \$0.05, an improvement of 81%;
- Net Cash Used in Operating Activities was \$1.0 million, an improvement of 86%; and
- Cash and Cash Equivalents were \$67.8 million at March 31, 2019.

### First Quarter 2019 and Recent Business Highlights

- Recognized revenue for the first time for the Envisia classifier in the first quarter of 2019.
- Grew genomic test volume to 9,162 tests in the first quarter of 2019, an increase of 33% compared with the first quarter of 2018.
- Received a final Medicare coverage determination for the Envisia classifier through the MoIDX program effective April 1, 2019, making the test a covered service for nearly 60 million Medicare beneficiaries nationwide.
- Received coverage for the Afirma Genomic Sequencing Classifier (GSC) under the U.S. Department of Defense TRICARE program for approximately 9.4 million uniformed service members, retirees and their families around the world.
- Received regulatory approval for the Envisia classifier from the New York State Department of Health, making the test available to patients in the state effective immediately.

### Strengthened Library of Clinical Evidence:

- Published clinical validation and utility study findings for the Envisia classifier in *The Lancet Respiratory Medicine*, demonstrating that the test can identify more than two-thirds of patients (70% sensitivity) with the hallmark pattern of idiopathic pulmonary fibrosis (IPF), with high accuracy (88% specificity), thus improving diagnosis – without the need for surgery.
- An independent real-world study on the Afirma GSC was published in *Thyroid* showing that at Brigham and Women's Hospital use of the test identified benign thyroid nodules nearly 40% more often than the original Afirma test. This

improved performance was due to the test's enhanced ability to distinguish benign from cancerous Hürthle cells, a common but hard-to-diagnose thyroid nodule subtype.

- Published a manuscript on the Afirma GSC in *BMS Systems Biology* showcasing the development of the classifier using RNA whole-transcriptome sequencing and machine learning, enabling improved diagnosis of Hürthle cell benign adenoma from carcinoma within this subtype of thyroid nodules.
- Presented Afirma Xpression Atlas data at the ENDO 2019, revealing new insights into the genomic underpinning of medullary thyroid cancer (MTC). This variant and fusion information may help guide physicians in the preoperative evaluation, surgical planning and targeted therapy selections for patients diagnosed with this rare, but aggressive, form of thyroid cancer.

#### Updated 2019 Financial Outlook

Veracyte is increasing its 2019 annual revenue guidance to a range of \$117 million to \$121 million from its prior guidance range of \$113 million to \$117 million. The company continues to expect full-year 2019 net cash used in operating activities to be in the range of \$4 million to \$6 million and to achieve operating cash flow breakeven before the end of this year.

#### Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company's website and will be available via the following link <https://edge.media-server.com/m6/p/jsjh76tc>.

The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company's website at <https://investor.veracyte.com/events-presentations>.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):	(855) 541-0980
International participant dial-in number:	(970) 315-0440
Conference I.D.:	9289499

#### About Veracyte

Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized five genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit [www.veracyte.com](http://www.veracyte.com) and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.

#### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our belief that we have a strong foundation in place to drive revenue growth and achieve operating cash flow breakeven before the end of 2019, our beliefs regarding momentum in our business and potential drivers of future growth, our first quarter 2019 performance and our expectations regarding full-year 2019 revenue and net cash used in operating activities, the success of our Afirma Xpression Atlas platform, our expectations regarding our ability to expand commercialization of our Percepta and Envisia Genomic Classifiers, our expectations regarding our strategic collaboration with Johnson & Johnson, our ability to drive revenue growth across our endocrinology and pulmonology franchises, our estimates of the number of people covered under the TRICARE program, our belief that published clinical validation and utility study finding for the Envisia classifier can improve diagnosis and decrease the need for surgery, study results demonstrating that the Afirma GSC test has an enhanced ability to distinguish benign from cancerous Hürthle cells, our belief that variant and fusion information from the Afirma Xpression Atlas data may help guide physicians in preoperative evaluation, surgical planning and targeted therapy selections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to our history of losses since inception; the commercialization, performance and acceptance of our Afirma, Percepta and Envisia classifiers; our dependence on a few payers for reimbursements and payments of our tests and a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our classifiers; our ability to increase usage of and reimbursement for the Afirma, Percepta and Envisia classifiers, as well as any future products we may develop or sell; our dependence on physicians and patients who decide whether to order and use our tests; the fluctuation of our quarterly operating results; our ability to comply with federal and state licensing requirements and other laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our dependence on supplies for equipment and other materials used for our tests; our ability to develop and commercialize new products and the timing and speed of commercialization; the amount by which use of our products is able to reduce invasive procedures and reduce healthcare costs; our ability to attract and retain key personnel; our ability to achieve sales penetration in complex commercial accounts; the occurrence and outcome of clinical studies; the timing and publication of study results; the potential for future clinical studies to contradict or undermine previously published clinical study results; the applicability of clinical results to actual outcomes; the continued application of clinical guidelines to our products and their inclusion in such clinical practice guidelines; our ability to compete; our ability to obtain capital when needed; and other risks set forth in the company's filings with the

Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2018. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.

**VERACYTE, INC.**  
**CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  
(Unaudited)  
(In thousands of dollars, except share and per share amounts)

	<u>Three Months Ended March 31,</u>	
	<u>2019</u>	<u>2018</u>
Revenue	\$ 29,529	\$ 20,041
Operating expenses:		
Cost of revenue	8,513	7,867
Research and development	3,435	3,675
Selling and marketing	12,477	11,543
General and administrative	6,904	5,644
Intangible asset amortization	267	267
Total operating expenses	<u>31,596</u>	<u>28,996</u>
Loss from operations	(2,067)	(8,955)
Interest expense	(303)	(448)
Other income, net	453	226
Net loss and comprehensive loss	<u>\$ (1,917)</u>	<u>\$ (9,177)</u>
Net loss per common share, basic and diluted	<u>\$ (0.05)</u>	<u>\$ (0.27)</u>
Shares used to compute net loss per common share, basic and diluted	<u>41,168,593</u>	<u>34,271,254</u>

**VERACYTE, INC.**  
**CONDENSED BALANCE SHEETS**  
(In thousands)

	<u>March 31,</u>	<u>December 31,</u>
	<u>2019</u>	<u>2018</u>
	<u>(Unaudited)</u>	<u>(See Note 1)</u>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 67,841	\$ 77,995
Accounts receivable	16,615	13,168
Supplies	3,768	3,402
Prepaid expenses and other current assets	2,392	2,387
Total current assets	<u>90,616</u>	<u>96,952</u>
Property and equipment, net	8,114	8,940
Right-of-use assets - finance lease, net	735	—
Right-of-use assets - operating lease	9,630	—
Finite-lived intangible assets, net	11,733	12,000
Goodwill	1,057	1,057
Restricted cash	603	603
Other assets	1,049	1,086
Total assets	<u>\$ 123,537</u>	<u>\$ 120,638</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 4,064	\$ 2,516
Accrued liabilities	8,788	9,186
Current portion of long-term debt	—	1,357
Current portion of finance lease liability	233	—
Current portion of operating lease liability	1,244	—
Total current liabilities	<u>14,329</u>	<u>13,059</u>
Long-term debt	12,854	23,925
Deferred rent, net of current portion	—	3,899
Operating lease liability, net of current portion	<u>12,582</u>	<u>—</u>

Total liabilities	39,765	40,883
Total stockholders' equity	83,772	79,755
Total liabilities and stockholders' equity	<u>\$ 123,537</u>	<u>\$ 120,638</u>

(1) The condensed balance sheet at December 31, 2018 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated February 25, 2019.

**VERACYTE, INC.**  
**CONDENSED STATEMENTS OF CASH FLOWS**  
(Unaudited)  
(in thousands of dollars)

	<u>Three Months Ended March 31,</u>	
	<u>2019</u>	<u>2018</u>
<b>Operating activities</b>		
Net loss	\$ (1,917)	\$ (9,177)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	945	980
Gain on disposal of property and equipment	(16)	—
Stock-based compensation	1,759	1,175
Other income	—	(93)
Amortization of debt issuance costs	8	8
Interest on end-of-term debt obligation	64	70
Changes in operating assets and liabilities:		
Accounts receivable	(3,447)	(482)
Supplies	(366)	767
Prepaid expenses and other current assets	(11)	(239)
Right-of-use assets - operating lease and operating lease liability	(80)	—
Other assets	37	(140)
Accounts payable	1,726	(510)
Accrued liabilities and deferred rent	287	228
Net cash used in operating activities	<u>(1,011)</u>	<u>(7,413)</u>
<b>Investing activities</b>		
Purchases of property and equipment	(765)	(227)
Proceeds from disposal of property and equipment	16	—
Net cash used in investing activities	<u>(749)</u>	<u>(227)</u>
<b>Financing activities</b>		
Payment of long-term debt	(12,500)	—
Proceeds from legal settlement regarding short-swing profits	—	403
Payment of finance lease liability	(75)	(71)
Proceeds from the exercise of common stock options and employee stock purchases	4,181	569
Net cash (used in) provided by financing activities	<u>(8,394)</u>	<u>901</u>
<b>Net decrease in cash, cash equivalents and restricted cash</b>	<u>(10,154)</u>	<u>(6,739)</u>
<b>Cash, cash equivalents and restricted cash at beginning of period</b>	<u>78,598</u>	<u>34,494</u>
<b>Cash, cash equivalents and restricted cash at end of period</b>	<u>\$ 68,444</u>	<u>\$ 27,755</u>
<b>Supplementary cash flow information of non-cash investing and financing activities:</b>		
Operating lease liability arising from obtaining right-of-use assets - operating lease	\$ 14,118	\$ —
Purchases of property and equipment included in accounts payable and accrued liabilities	\$ 95	\$ 56
Interest paid on debt	\$ 228	\$ 356

**CASH, CASH EQUIVALENTS AND RESTRICTED CASH**  
(Unaudited)  
(In thousands of dollars)

	<u>March 31, December 31,</u>	
	<u>2019</u>	<u>2018</u>
Cash and cash equivalents	\$ 67,841	\$ 77,995

Restricted cash	<u>603</u>	<u>603</u>
Total cash, cash equivalents and restricted cash	<u>\$ 68,444</u>	<u>\$ 78,598</u>

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190430006021/en/>

Source: Veracyte, Inc.

**Investor and Media Contact:**

Angie McCabe, 650-243-6371

Vice President, Investor Relations and Corporate Communications

[angie@veracyte.com](mailto:angie@veracyte.com)